Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ST 1435

Known as: ST-1435 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Because of its unique features, the contraceptive effectiveness and tolerance during breast-feeding of 16-methylene-17 alpha… Expand
1992
1992
A new modified subdermal implant releasing the potent progestin ST-1435 was studied in eleven fertile-aged women. These implants… Expand
1991
1991
The synthetic progestin ST-1435 was administered transdermally to six healthy women during the late luteal phase. The steroid was… Expand
1990
1990
A subcutaneous contraceptive capsule releasing progestin ST-1435 was used by 6 breast-feeding women. One to three paired milk and… Expand
1985
1985
We summarize the hormonal profiles of women at different stages of inhibition of ovarian function during sustained-release… Expand
1984
1984
ST-1465 a new progestogen has some characteristics that make it promising as a subcutaneous contraceptive in lactating women. ST… Expand
1983
1983
The nonprotein bound percentage of ST-1435 was measured by centrifugal ultrafiltration dialysis in undiluted female serum at 37… Expand
  • table I
1982
1982
Three women received one subcutaneous SilasticR capsule containing 40 mg of ST-1435 for contraception. Plasma levels of ST-1435… Expand
1981
1981
Abstract An RIA for a new progestin, ST-1435, was developed. Plasma concentrations of this steroid were measured in three women… Expand
1981
1981
An RIA for a new progestin, ST-1435, was developed. Plasma concentrations of this steroid were measured in three women having… Expand